2-CHLORO-3,6-DIFLUOROBENZALDEHYDE

We are 2-CHLORO-3,6-DIFLUOROBENZALDEHYDE CAS:261762-39-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-CHLORO-3,6-DIFLUOROBENZALDEHYDE
CAS.NO:261762-39-4
Synonyms:2-Chloro-3,6-Difluorobenzaldehyde;
Molecular Formula:C7H3ClF2O
Molecular Weight:176.54800
 
Physical and Chemical Properties:
Density:1.453;
Melting point:46-50oC;
Boiling point:206.4oC;
Flash point:230oF;
Index of Refraction:1.536;
 
Specification:
Appearance:White to yellow crystalline powder
Purity(GC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis

2-CHLORO-3,6-DIFLUOROBENZALDEHYDE


Related News: By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.ETHYL 5-NITROBENZOFURAN-2-CARBOXYLATE CAS:69404-00-8 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).54528-00-6 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).3-chloropyridine-2-carboxylic acid Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
L-Citrulline View Details
1,4-Diisopropenylbenzene View Details
(2E)-2-(1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-ylidene)acetonitrile View Details
Trimethylsilyl trifluoromethanesulfonate manufacturer 5-(2,4,6-trimethylphenyl)cyclohexane-1,3-dione manufacturer methyl 3-(2-methoxy-5-methylphenyl)-3-phenylpropanoate manufacturer 2-Chloro-4-Methylbenzotrifluoride manufacturer phthalic anhydride manufacturer